COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review

• Published in: Clinical immunology (Orlando, Fla.) Vol. 243; p. 109097
• Main Authors: Drzymalla, Emily, Green, Ridgely Fisk, Knuth, Martha, Khoury, Muin J., Dotson, W. David, Gundlapalli, Adi
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.10.2022; Academic Press
• Subjects: COVID-19; Inborn errors of immunity; Primary immunodeficiency; Public health; Review; SARS-CoV-2; COVID-19; SARS-CoV-2; Inborn errors of immunity; Public health; Primary immunodeficiency
• ISSN: 1521-6616; 1521-7035
• DOI: 10.1016/j.clim.2022.109097

A better understanding of COVID-19 in people with primary immunodeficiency (PI), rare inherited defects in the immune system, is important for protecting this population, especially as population-wide approaches to mitigation change. COVID-19 outcomes in the PI population could have broader public health implications because some people with PI might be more likely to have extended illnesses, which could lead to increased transmission and emergence of variants. We performed a systematic review on COVID-19-associated morbidity and mortality in people with PI. Of the 1114 articles identified through the literature search, we included 68 articles in the review after removing 1046 articles because they were duplicates, did not involve COVID-19, did not involve PI, were not in English, were commentaries, or could not be accessed. The 68 articles included outcomes for 459 people with PI and COVID-19. Using data from these 459 people, we calculated a case fatality rate of 9%, hospitalization rate of 49%, and oxygen supplementation rate of 29%. Studies have indicated that a number of people with PI showed at least some immune response to COVID-19 vaccination, with responses varying by type of PI and other factors, although vaccine effectiveness against hospitalization was lower in the PI population than in the general population. In addition to being up-to-date on vaccinations, current strategies for optimizing protection for people with PI can include pre-exposure prophylaxis for those eligible and use of therapeutics. Overall, people with PI, when infected, tested positive and showed symptoms for similar lengths of time as the general population. However, a number of people with x-linked agammaglobulinemia (XLA) or other B-cell pathway defects were reported to have prolonged infections, measured by time from first positive SARS-CoV-2 test to first negative test. As prolonged infections might increase the likelihood of genetic variants emerging, SARS-CoV2 isolates from people with PI and extended illness would be good candidates to prioritize for whole genome sequencing. •9% case fatality rate, 49% hospitalization rate among people with PI•Vaccine effectiveness against hospitalization lower in the PI population.•People with PI and prolonged infection candidates for whole viral genome sequencing•Vaccination, pre-exposure prophylaxis, therapeutics important for people with PI